BRYXTA 400MG INJ

Product Description

• Active Ingredient: Bevacizumab 400 mg.
• Form: Solution for intravenous (IV) infusion, administered by a healthcare professional in a clinical setting.
• Mechanism of Action: It binds to a protein called vascular endothelial growth factor (VEGF), which is essential for the creation of blood vessels within tumors (angiogenesis). By blocking VEGF, the medicine limits the blood flow to cancer cells, causing the tumor to shrink or stop growing.
Uses
Bryxta 400mg is used, often in combination with other chemotherapy drugs, to treat several types of cancer, including:
• Metastatic colorectal cancer (cancer of the colon or rectum that has spread)
• Advanced non-small cell lung cancer
• Metastatic breast cancer (usually HER2-negative tumors)
• Advanced kidney cancer (renal cell carcinoma)
• Cervical cancer (persistent, recurrent, or metastatic)
• Ovarian, fallopian tube, or primary peritoneal cancer
• Glioblastoma (a type of brain tumor, typically in recurrent cases)
• Hepatocellular carcinoma (liver cancer)
Important Precautions and Side Effects
• Administration: This medication must not be self-administered. It is given as an intravenous infusion by a doctor or nurse.
• Surgery: Bryxta can impair wound healing and increase the risk of bleeding. Patients should not have major surgery for at least 28 days before or after receiving the injection, or until the wound has fully healed.
• Pregnancy/Breastfeeding: It is contraindicated during pregnancy and breastfeeding. Women of childbearing potential must use effective contraception during treatment and for at least six months after the final dose.
• Common Side Effects: Include fatigue, constipation, loss of appetite, fever, nosebleeds, headache, dry skin, high blood pressure, and changes in speech or taste.
• Serious Side Effects: Can include severe bleeding (e.g., in the stomach or intestines), blood clots, high blood pressure, protein in the urine, and heart problems. Patients should seek immediate medical attention for symptoms like severe headache, vision changes, confusion, or unusual bleeding.